9966 Stock Overview
A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Alphamab Oncology Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.40 |
| 52 Week High | HK$7.61 |
| 52 Week Low | HK$2.00 |
| Beta | 0.61 |
| 1 Month Change | 68.18% |
| 3 Month Change | 117.65% |
| 1 Year Change | 65.18% |
| 3 Year Change | -7.38% |
| 5 Year Change | -52.13% |
| Change since IPO | -45.19% |
Recent News & Updates
Recent updates
Market Participants Recognise Alphamab Oncology's (HKG:9966) Revenues Pushing Shares 88% Higher
Feb 28
After Leaping 31% Alphamab Oncology (HKG:9966) Shares Are Not Flying Under The Radar
Nov 14Alphamab Oncology (HKG:9966) Stocks Shoot Up 91% But Its P/S Still Looks Reasonable
Sep 30Some Alphamab Oncology (HKG:9966) Shareholders Look For Exit As Shares Take 48% Pounding
Jun 20Alphamab Oncology's (HKG:9966) Shares Climb 27% But Its Business Is Yet to Catch Up
May 06Optimistic Investors Push Alphamab Oncology (HKG:9966) Shares Up 27% But Growth Is Lacking
Mar 13Subdued Growth No Barrier To Alphamab Oncology's (HKG:9966) Price
Jan 17Slammed 40% Alphamab Oncology (HKG:9966) Screens Well Here But There Might Be A Catch
May 21Newsflash: Alphamab Oncology (HKG:9966) Analysts Have Been Trimming Their Revenue Forecasts
Mar 01Is Alphamab Oncology (HKG:9966) Using Debt Sensibly?
Oct 04Is Alphamab Oncology (HKG:9966) A Risky Investment?
May 21Shareholder Returns
| 9966 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 33.6% | 1.4% | -0.7% |
| 1Y | 65.2% | 35.6% | 28.8% |
Return vs Industry: 9966 exceeded the Hong Kong Biotechs industry which returned 35.6% over the past year.
Return vs Market: 9966 exceeded the Hong Kong Market which returned 28.8% over the past year.
Price Volatility
| 9966 volatility | |
|---|---|
| 9966 Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.5% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 9966's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 9966's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 429 | Ting Xu | www.alphamabonc.com |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company’s product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders.
Alphamab Oncology Fundamentals Summary
| 9966 fundamental statistics | |
|---|---|
| Market cap | HK$7.12b |
| Earnings (TTM) | -HK$231.22m |
| Revenue (TTM) | HK$274.37m |
26.0x
P/S Ratio-30.8x
P/E RatioIs 9966 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9966 income statement (TTM) | |
|---|---|
| Revenue | CN¥255.87m |
| Cost of Revenue | CN¥52.88m |
| Gross Profit | CN¥202.99m |
| Other Expenses | CN¥418.62m |
| Earnings | -CN¥215.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 25, 2025
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 79.33% |
| Net Profit Margin | -84.27% |
| Debt/Equity Ratio | 19.6% |
How did 9966 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 21:48 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alphamab Oncology is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wangbin Zhou | Citigroup Inc |
| null null | CLSA |
| null null | Guoyuan Securities (HK) Ltd |